# Inetetamab Plus Chemotherapy ± PD-1/PD-L1 in HER2+ Advanced Biliary Cancer

> **NCT06818773** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Eastern Hepatobiliary Surgery Hospital** · enrollment: 35 (estimated)

## Conditions studied

- Metastatic Biliary Tract Cancer
- HER2 Positive

## Interventions

- **DRUG:** Inetetamab + Gemcitabine + Cisplatin ± PD-1/PD-L1 inhibitor

## Key facts

- **NCT ID:** NCT06818773
- **Lead sponsor:** Eastern Hepatobiliary Surgery Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-02
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2025-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06818773

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06818773, "Inetetamab Plus Chemotherapy ± PD-1/PD-L1 in HER2+ Advanced Biliary Cancer". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT06818773. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*